SynthesisEuropean urology2023
Genome-wide Association Study of Bladder Cancer Reveals New Biological and Translational Insights.
Open access · goldAbstract readMeta-Analysis
In one paragraph
Synthesis in European urology, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 40 papers, 2 of them syntheses that pooled it.
0numbers the graph read from it
0cells of the map it votes in
40citing papers in PubMed, 2 pooled it
21.9field-weighted citation impact, top 1% of its field
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
40 citing papers in PubMed, 2 syntheses or guidelines pooled it, 69 citations in OpenAlex.
- Smoking and bladder cancer: insights into pathogenesis and public health implications from a bibliometric analysis (1999-2023).Substance abuse treatment, prevention, and policy · 2025Pooled it
- Genome-wide association study and Mendelian randomization analyses reveal insights into bladder cancer etiology.JNCI cancer spectrum · 2025Pooled it
- Development and validation of artificial intelligence-based model for bladder cancer immunophenotyping using whole slide images.NPJ precision oncology · 2026Article
- Cigarette Smoking-RegulatedEnvironment & health (Washington, D.C.) · 2026Article
- Integrative screening identifies functional variants and VNTRs underlying GWAS signals at the 5p15.33 multi-cancer susceptibility locus.medRxiv : the preprint server for health sciences · 2026Article
- Single-cell transcriptomic profiling combined with Mendelian randomization illuminates molecular drivers of bladder cancer.Molecular genetics and genomics : MGG · 2026Article
- Cigarette smoking combines with genetic variants to regulate FOXN3 and associate with bladder cancer risk.Archives of toxicology · 2026Article
- Telomere Length Abnormality: Investigating Approaches and Correlations with Cancer, Bone Marrow Failure and Hematological Malignancies.Biomedicines · 2025Review
- Global, regional, and national burden of bladder cancer from 1990 to 2021 with projections to 2050: insights from the global burden of disease study and Mendelian randomization analysis.Infectious agents and cancer · 2025Article
- Gene and pathway analysis of genome-wide genetic associations of bladder cancer.Current urology · 2025Article
- Exploring the impact of chronotype, chrononutrition and lifestyle on bladder cancer.International urology and nephrology · 2025Article
- Smoking promotes the progression of bladder cancer through FOXM1/CKAP2L axis.Journal of translational medicine · 2025Article
- Integrative Analysis ofInternational journal of molecular sciences · 2025Article
- Lifetime water arsenic, genetic susceptibility, and bladder cancer in the New England Bladder Cancer Study.JNCI cancer spectrum · 2025Article
- Solvent Exposure, Genetic Susceptibility, and Risk of Bladder Cancer.Cancer prevention research (Philadelphia, Pa.) · 2025Article
- The role of CDK8 gene polymorphisms in bladder cancer susceptibility and prognosis: a study in the Chinese Han population.BMC cancer · 2025Article
- Genetic regulation of TERT splicing affects cancer risk by altering cellular longevity and replicative potential.Nature communications · 2025Article
- Transcriptome-wide association study identifies genes associated with bladder cancer risk.Scientific reports · 2025Article
- [Urothelial carcinoma of the upper and lower urinary tract-which risk factors make early detection worthwhile?]Urologie (Heidelberg, Germany) · 2025Review
- Decoding monocyte heterogeneity in sepsis: a single-cell apoptotic signature for immune stratification and guiding precision therapy.Frontiers in pharmacology · 2025Article
Corrections and comments
- Commented on by
Authors and funding
101 authors at 20 institutions in 12 countries.
Stella KoutrosOccupational and Environmental Epidemiology Branch, Division of Cancer Epidemiology and Genetics, National Cancer Institute, Bethesda, MD, USA. Electronic address: koutross@mail.nih.gov.
Lambertus A KiemeneyDepartment for Health Evidence, Radboud University Medical Center, Nijmegen, The Netherlands.
Parichoy Pal ChoudhuryTrans-Divisional Research Program, Division of Cancer Epidemiology and Genetics, National Cancer Institute, Bethesda, MD, USA; American Cancer Society, Atlanta, GA, USA.
Roger L MilneCancer Epidemiology Division, Cancer Council Victoria, Melbourne, Australia; Centre for Epidemiology and Biostatistics, Melbourne School of Population and Global Health, The University of Melbourne, Melbourne, Australia; Precision Medicine, School of Clinical Sciences at Monash Health, Monash University, Clayton, Australia.
Evangelina Lopez de MaturanaGenetic and Molecular Epidemiology Group, Spanish National Cancer Research Centre (CNIO) and CIBERONC, Madrid, Spain.
Yuanqing YeZhejiang University, Hangzhou, China.
Vijai JosephMemorial Sloan Kettering Cancer Center, New York, NY, USA.
Oscar Florez-VargasLaboratory of Translational Genomics, Division of Cancer Epidemiology and Genetics, National Cancer Institute, Bethesda, MD, USA.
Lars DyrskjøtDepartment of Clinical Medicine, Aarhus University, Aarhus, Denmark.
Jonine FigueroaUsher Institute, University of Edinburgh, Edinburgh, UK; Integrative Tumor Epidemiology Branch, Division of Cancer Epidemiology and Genetics, National Cancer Institute, Bethesda, MD, USA.
Diptavo DuttaIntegrative Tumor Epidemiology Branch, Division of Cancer Epidemiology and Genetics, National Cancer Institute, Bethesda, MD, USA.
Graham G GilesCancer Epidemiology Division, Cancer Council Victoria, Melbourne, Australia; Centre for Epidemiology and Biostatistics, Melbourne School of Population and Global Health, The University of Melbourne, Melbourne, Australia; Precision Medicine, School of Clinical Sciences at Monash Health, Monash University, Clayton, Australia.
Michelle A T HildebrandtUniversity of Texas MD Anderson Cancer Center, Houston, TX, USA.
Kenneth OffitMemorial Sloan Kettering Cancer Center, New York, NY, USA.
Manolis KogevinasInstituto de Salud Global, Barcelona, Spain.
Elisabete WeiderpassInternational Agency for Research on Cancer, Lyon, France.
Marjorie L McCulloughPopulation Science, American Cancer Society, Atlanta, GA, USA.
Neal D FreedmanMetabolic Epidemiology Branch, Division of Cancer Epidemiology and Genetics, National Cancer Institute, Bethesda, MD, USA.
Demetrius AlbanesMetabolic Epidemiology Branch, Division of Cancer Epidemiology and Genetics, National Cancer Institute, Bethesda, MD, USA.
Charles KooperbergDivision of Public Health Sciences, Fred Hutchinson Cancer Center, Seattle, WA, USA.
Victoria K CortessisDepartment of Population and Public Health Sciences, Epidemiology and Genetics, University of Southern California, Los Angeles, CA, USA.
Margaret R KaragasDepartment of Epidemiology, Geisel School of Medicine at Dartmouth, Hanover, NH, USA.
Alison JohnsonVermont Department of Health, Burlington, VT, USA.
Molly R SchwennRetired, Maine Cancer Registry, Augusta, ME, USA.
Dalsu BarisOccupational and Environmental Epidemiology Branch, Division of Cancer Epidemiology and Genetics, National Cancer Institute, Bethesda, MD, USA.
Helena FurbergMemorial Sloan Kettering Cancer Center, New York, NY, USA.
Dean F BajorinMemorial Sloan Kettering Cancer Center, New York, NY, USA.
Olivier CussenotCentre de Recherche sur les Pathologies Prostatiques et Urologiques, Paris, France.
Geraldine Cancel-TassinCentre de Recherche sur les Pathologies Prostatiques et Urologiques, Paris, France; GRC 5 Predictive Onco-Urology, Sorbonne University, Paris, France.
Simone BenhamouINSERM U1018, Research Centre on Epidemiology and Population Health, Villejuif, France.
Peter KraftDepartment of Epidemiology, Harvard T.H. Chan School of Public Health, Boston, MA, USA.
Stefano PorruDepartment of Diagnostics and Public Health, Section of Occupational Medicine, University of Verona, Verona, Italy.
Angela CartaDepartment of Diagnostics and Public Health, Section of Occupational Medicine, University of Verona, Verona, Italy.
Timothy BishopSection of Epidemiology and Biostatistics, Leeds Institute of Cancer and Pathology, University of Leeds, Leeds, UK.
Melissa C SoutheyCancer Epidemiology Division, Cancer Council Victoria, Melbourne, Australia; Precision Medicine, School of Clinical Sciences at Monash Health, Monash University, Clayton, Australia; Department of Clinical Pathology, The University of Melbourne, Parkville, Australia.
Giuseppe MatulloDepartment of Medical Sciences, University of Turin, Turin, Italy.
Tony FletcherLondon School of Hygiene and Tropical Medicine, London, UK.
Rajiv KumarDivision of Functional Genome Analysis, German Cancer Research Center, Heidelberg, Germany.
Jack A TaylorEpidemiology Branch and Epigenetic and Stem Cell Biology Laboratory, National Institute of Environmental Health Sciences, National Institutes of Health, Research Triangle Park, NC, USA.
Philippe LamyDepartment of Molecular Medicine, Aarhus University Hospital, Aarhus, Denmark.
Frederik PripDepartment of Molecular Medicine, Aarhus University Hospital, Aarhus, Denmark.
Mark KaliszEpithelial Carcinogenesis Group, Spanish National Cancer Research Centre (CNIO) and CIBERONC, Madrid, Spain.
Stephanie J WeinsteinMetabolic Epidemiology Branch, Division of Cancer Epidemiology and Genetics, National Cancer Institute, Bethesda, MD, USA.
Jan G HengstlerLeibniz Research Centre for Working Environment and Human Factors at TU Dortmund (IfADo), Dortmund, Germany.
Silvia SelinskiLeibniz Research Centre for Working Environment and Human Factors at TU Dortmund (IfADo), Dortmund, Germany.
Mark HarlandSection of Epidemiology and Biostatistics, Leeds Institute of Cancer and Pathology, University of Leeds, Leeds, UK.
Mark TeoSection of Epidemiology and Biostatistics, Leeds Institute of Cancer and Pathology, University of Leeds, Leeds, UK.
Anne E KiltieRowett Institute, School of Medicine, Medical Sciences and Nutrition, University of Aberdeen, Aberdeen, UK.
Adonina TardónDepartment of Preventive Medicine, Universidad de Oviedo, ISPA and CIBERESP, Spain.
Consol SerraCenter for Research in Occupational Health, Universitat Pompeu Fabra, Hospital del Mar Medical Research Institut, CIBERESP, Barcelona, Spain.
Alfredo CarratoDepartment of Medicine, Alcalá University, IRYCIS, CIBERONC, Madrid, Spain.
Reina García-ClosasHospital Universitario de Canarias, Tenerife, Spain.
Josep LloretaHospital del Mar, Universitat Pompeu Fabra, Barcelona, Spain.
Alan SchnedDepartment of Pathology, Dartmouth Medical School, Hanover, NH, USA.
Petra LenzCancer Genomics Research Laboratory, Leidos Biomedical Research, Frederick National Laboratory for Cancer Research, Frederick, MD, USA.
Elio RiboliSchool of Public Health, Imperial College London, London, UK.
Paul BrennanInternational Agency for Research on Cancer, Lyon, France.
Anne TjønnelandDanish Cancer Society Research Center, Copenhagen, Denmark.
Thomas OttoDepartment of Urology, Rheinland Klinikum, Lukaskrankenhaus, Neuss, Germany.
Daniel OvsiannikovDepartment of Urology, St.-Josefs-Hospital, Dortmund, Germany.
Frank VolkertDepartment of Urology, Evangelic Hospital, Paul Gerhardt Foundation, Lutherstadt Wittenberg, Germany.
Sita H VermeulenDepartment for Health Evidence, Radboud University Medical Center, Nijmegen, The Netherlands.
Katja K AbenDepartment for Health Evidence, Radboud University Medical Center, Nijmegen, The Netherlands; Netherlands Comprehensive Cancer Organisation, Utrecht, The Netherlands.
Tessel E GaleslootDepartment for Health Evidence, Radboud University Medical Center, Nijmegen, The Netherlands.
Constance TurmanDepartment of Epidemiology, Harvard T.H. Chan School of Public Health, Boston, MA, USA.
Immaculata De VivoDepartment of Epidemiology, Harvard T.H. Chan School of Public Health, Boston, MA, USA; Department of Medicine, Channing Division of Network Medicine, Brigham and Women's Hospital and Harvard Medical School, Boston, MA, USA.
Edward GiovannucciDepartment of Epidemiology, Harvard T.H. Chan School of Public Health, Boston, MA, USA.
David J HunterDepartment of Epidemiology, Harvard T.H. Chan School of Public Health, Boston, MA, USA; Nuffield Department of Population Health, University of Oxford, Oxford, UK.
Chancellor HohenseeDivision of Public Health Sciences, Fred Hutchinson Cancer Center, Seattle, WA, USA.
Rebecca HuntDivision of Public Health Sciences, Fred Hutchinson Cancer Center, Seattle, WA, USA.
Alpa V PatelPopulation Science, American Cancer Society, Atlanta, GA, USA.
Wen-Yi HuangMetabolic Epidemiology Branch, Division of Cancer Epidemiology and Genetics, National Cancer Institute, Bethesda, MD, USA.
Gudmar ThorleifssondeCODE genetics/Amgen, Reykjavik, Iceland.
Manuela Gago-DominguezFundación Pública Galega de Medicina Xenómica, Servicio Galego de Saude, Health Research Institute of Santiago de Compostela, Santiago de Compostela, Spain.
Pilar AmianoMinistry of Health of the Basque Government, Sub Directorate for Public Health and Addictions of Gipuzkoa, San Sebastian, Spain; Biodonostia Health Research Institute, Epidemiology of Chronic and Communicable Diseases Group, San Sebastian, Spain; Spanish Consortium for Research on Epidemiology and Public Health (CIBERESP), Instituto de Salud Carlos III, Madrid, Spain.
Klaus GolkaLeibniz Research Centre for Working Environment and Human Factors at TU Dortmund (IfADo), Dortmund, Germany.
Mariana C SternDepartment of Population and Public Health Sciences, Norris Comprehensive Cancer Center, Keck School of Medicine, University of Southern California, Los Angeles, CA, USA.
UROMOL Consortium
Wusheng YanLaboratory of Translational Genomics, Division of Cancer Epidemiology and Genetics, National Cancer Institute, Bethesda, MD, USA.
Jia LiuCancer Genomics Research Laboratory, Leidos Biomedical Research, Frederick National Laboratory for Cancer Research, Frederick, MD, USA.
Shengchao Alfred LiCancer Genomics Research Laboratory, Leidos Biomedical Research, Frederick National Laboratory for Cancer Research, Frederick, MD, USA.
Shilpa KattaCancer Genomics Research Laboratory, Leidos Biomedical Research, Frederick National Laboratory for Cancer Research, Frederick, MD, USA.
Amy HutchinsonCancer Genomics Research Laboratory, Leidos Biomedical Research, Frederick National Laboratory for Cancer Research, Frederick, MD, USA.
Belynda HicksCancer Genomics Research Laboratory, Leidos Biomedical Research, Frederick National Laboratory for Cancer Research, Frederick, MD, USA.
William A WheelerInformation Management Services, Inc, Rockville, MD, USA.
Mark P PurdueOccupational and Environmental Epidemiology Branch, Division of Cancer Epidemiology and Genetics, National Cancer Institute, Bethesda, MD, USA.
Katherine A McGlynnMetabolic Epidemiology Branch, Division of Cancer Epidemiology and Genetics, National Cancer Institute, Bethesda, MD, USA.
Cari M KitaharaRadiation Epidemiology Branch, Division of Cancer Epidemiology and Genetics, National Cancer Institute, Bethesda, MD, USA.
Christopher A HaimanCenter for Genetic Epidemiology, Department of Population and Public Health Sciences, Keck School of Medicine, University of Southern California, Los Angeles, CA, USA.
Mark H GreeneClinical Genetics Branch, Division of Cancer Epidemiology and Genetics, National Cancer Institute, Bethesda, MD, USA.
Thorunn RafnardeCODE genetics/Amgen, Reykjavik, Iceland.
Nilanjan ChatterjeeJohns Hopkins University, Baltimore, MD, USA.
Stephen J ChanockOffice of the Director, Division of Cancer Epidemiology and Genetics, National Cancer Institute, Bethesda, MD, USA.
Xifeng WuZhejiang University, Hangzhou, China.
Francisco X RealEpithelial Carcinogenesis Group, Spanish National Cancer Research Centre (CNIO) and CIBERONC, Madrid, Spain; Departament de Medicina i Ciències de la Vida, Universitat Pompeu Fabra, Barcelona, Spain.
Debra T SilvermanOccupational and Environmental Epidemiology Branch, Division of Cancer Epidemiology and Genetics, National Cancer Institute, Bethesda, MD, USA.
Montserrat Garcia-ClosasTrans-Divisional Research Program, Division of Cancer Epidemiology and Genetics, National Cancer Institute, Bethesda, MD, USA.
Kari StefanssondeCODE genetics/Amgen, Reykjavik, Iceland.
Ludmila Prokunina-OlssonLaboratory of Translational Genomics, Division of Cancer Epidemiology and Genetics, National Cancer Institute, Bethesda, MD, USA.
Núria MalatsGenetic and Molecular Epidemiology Group, Spanish National Cancer Research Centre (CNIO) and CIBERONC, Madrid, Spain.
Nathaniel RothmanOccupational and Environmental Epidemiology Branch, Division of Cancer Epidemiology and Genetics, National Cancer Institute, Bethesda, MD, USA.
National Cancer Institute · USLeidos (United States) · USMemorial Sloan Kettering Cancer Center · USRadboud University Nijmegen · NLAmerican Cancer Society · USdeCODE Genetics (Iceland) · ISFred Hutch Cancer Center · USHarvard University · USSpanish National Cancer Research Centre · ESTU Dortmund University · DEUniversity of Leeds · GBUniversity of Southern California · USAarhus University Hospital · DKCentre international de recherche sur le cancer · FRDartmouth College · USThe University of Melbourne · AUUniversitat Pompeu Fabra · ESUniversity of Verona · ITZhejiang University · CNAarhus University · DK
Funding
The Patient-Reported Outcomes, Community-Engagement and Language (PRO-CEL) CoreP30CA008748 · NCI · SLOAN-KETTERING INSTITUTE FOR CANCER RES · 1985 to 2025
$88.4MTHE PURPOSE OF THIS MODIFICATION IS TO DE-OBLIGATE NHLBI FUNDING FROM THE WOMEN'S HEALTH INITIATIVE (WHI) - CLINICAL COORDINATING CENTER (CCC).75N92021D00001 · FRED HUTCHINSON CANCER CENTER · 2025 to 2025
$9.3MLaboratory of Translational GenomicsZIACP010201 · DIVISION OF CANCER EPIDEMIOLOGY AND GENETICS · 2025 to 2025
$5.8MProbing cytosolic nucleic acid sensing pathways in cancerR01CA256188 · NCI · WEILL MEDICAL COLL OF CORNELL UNIV · 2022 to 2025
$2.8MWOMEN'S HEALTH INITIATIVE (WHI) REGIONAL CENTER (RC): TASK AREA A AND A275N92021D00002 · STATE UNIVERSITY OF NEW YORK AT BUFFALO · 2025 to 2025
$1.2MWOMEN'S HEALTH INITIATIVE (WHI) REGIONAL CENTER (RC): TASK AREA A AND A275N92021D00004 · STANFORD UNIVERSITY · 2025 to 2025
$1.1MWOMEN'S HEALTH INITIATIVE (WHI) REGIONAL CENTER (RC): TASK AREA A AND A275N92021D00005 · WAKE FOREST UNIVERSITY HEALTH SCIENCES · 2025 to 2025
$47kWOMEN'S HEALTH INITIATIVE (WHI) REGIONAL CENTER (RC): TASK AREA A AND A275N92021D00003 · OHIO STATE UNIVERSITY · 2025 to 2025
$39kCGEMSZ01CP010187 · CANCER EPIDEMIOLOGY AND GENETICS · 2005 to 2005
–Cancer Research UK 29186Intramural NIH HHS Z01 CP010187Intramural NIH HHS Z99 CA999999NCI NIH HHS P30 CA008748NCI NIH HHS P50 CA221745NCI NIH HHS R01 CA256188NCI NIH HHS R21 CA266660NHLBI NIH HHS 75N92021D00001NHLBI NIH HHS 75N92021D00002WHI NIH HHS 75N92021D00003WHI NIH HHS 75N92021D00004WHI NIH HHS 75N92021D00005World Health Organization 001
Abstract
backgroundGenomic regions identified by genome-wide association studies (GWAS) for bladder cancer risk provide new insights into etiology.
objectiveTo identify new susceptibility variants for bladder cancer in a meta-analysis of new and existing genome-wide genotype data. DESIGN, SETTING, AND
participantsData from 32 studies that includes 13,790 bladder cancer cases and 343,502 controls of European ancestry were used for meta-analysis. OUTCOME MEASUREMENTS AND STATISTICAL ANALYSES: Log-additive associations of genetic variants were assessed using logistic regression models. A fixed-effects model was used for meta-analysis of the results. Stratified analyses were conducted to evaluate effect modification by sex and smoking status. A polygenic risk score (PRS) was generated on the basis of known and novel susceptibility variants and tested for interaction with smoking. RESULTS AND LIMITATIONS: Multiple novel bladder cancer susceptibility loci (6p.22.3, 7q36.3, 8q21.13, 9p21.3, 10q22.1, 19q13.33) as well as improved signals in three known regions (4p16.3, 5p15.33, 11p15.5) were identified, bringing the number of independent markers at genome-wide significance (p < 5 × 10
conclusionsWe report novel loci associated with risk of bladder cancer that provide clues to its biological underpinnings. Using 24 independent markers, we constructed a PRS to stratify lifetime risk. The PRS combined with smoking history, and other established risk factors, has the potential to inform future screening efforts for bladder cancer. PATIENT SUMMARY: We identified new genetic markers that provide biological insights into the genetic causes of bladder cancer. These genetic risk factors combined with lifestyle risk factors, such as smoking, may inform future preventive and screening strategies for bladder cancer.
Indexed as
Arylamine N-AcetyltransferaseUrinary Bladder NeoplasmsAdaptor Proteins, Signal TransducingFemaleGenetic Predisposition to DiseaseGenome-Wide Association StudyGenotypeHumansMaleMembrane ProteinsMicrotubule-Associated ProteinsPolymorphism, Single NucleotideProspective StudiesRisk FactorsAdaptor Proteins, Signal TransducingArylamine N-AcetyltransferaseMembrane ProteinsMicrotubule-Associated ProteinsNAT2 protein, humanPAG1 protein, humanTACC3 protein, humanBladder cancerGene-environment interactionGenome-Wide Association Study (GWAS)Germline genetics
Identifiers
What Socratic holds
Textmetadata
LicenceTDM
Read underepoch 390
Registered trials
None linked
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.